Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Sanofi is a global healthcare company. Among their duties are researching disease causes, determining starting points for drug treatment, developing drugs, producing active ingredients, and delivering finished drugs and active ingredients. Specialists in vaccines, rare diseases, rare blood disorders, neurology, immunology, oncology, diabetes, cardiovascular diseases, and consumer healthcare.

Bayer Schering Pharma AG is a research-centered pharmaceutical company that was formed by the merger of Schering with Bayer on 29 December 2006. The company was originally founded in 1851 by Ernst Christian Friedrich Schering. The company employs more than 26,000 people in 140 subsidiaries all over the world. The company's headquarters are in Berlin-Wedding, Germany and the forerunner company Schering's annual gross revenue was nearly € 5 billion. They retain the largest German manufacturing facility which is located in Bergkamen. The company focuses on the business areas of gynaecology and andrology, oncology, and also special therapeutics, diagnostical devices, and nuclear medicine. Schering's best-known product is their line of combined oral contraceptive pills. Through Bayer Healthcare AG, Bayer Schering Pharma is a full member of the European Federation of Pharmaceutical Industries and Associations.

Cerecin is a healthcare company that develops novel evidence-based therapeutics and products that aim to help people. Cerecin develops novel evidence-based therapeutics and products that aim to help millions of people. These solutions are designed to target conditions ranging from memory impairment to Alzheimer’s disease and other devastating neurological diseases. The company was founded in 2001 and is based in Denver, Colorado.

Scidera Genomics LLC is an American company, with operations in Canada and the United States, that develops and commercializes biotechnology-based products to help improve animal health. It was founded by Adelene Q. Perkins and Robert A. Curtis. Scidera Genomics LLC was acquired by Neogen Corp. on January 02, 2013 for $3.40 million.

CuraGen Corporation is a biopharmaceutical development company that develops novel therapeutics for the treatment of cancer in the United States and Europe. Its therapeutics is based on novel targets from the human genome that play a role in proven mechanisms underlying disease. The Company's strategy continues to be focused on advancing its pipeline of pipeline of protein, antibody, and small molecule drugs in the areas of oncology, inflammatory diseases, and diabetes, promising therapeutics through clinical and preclinical development. CuraGen Corporation was founded in 1991 and is headquartered in Branford, Connecticut. As of October 1, 2009, CuraGen Corporation operates as a subsidiary of Celldex Therapeutics, Inc.

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.

Aventis Pharma Deutschland GmbH produces pharmaceutical products. It offers prescription drugs, human vaccines, and therapeutic proteins businesses. Aventis Pharma Deutschland plans and designs plants and process control systems in the areas of active ingredients production and finished drugs. The company is headquartered in Frankfurt am Main, Germany.

Board of Trustees of Michigan State University, part of Michigan State University, is an American company that trusts Except Educational Religious.

Kadmon Corporation, a biopharmaceutical company, offers products and services for the treatment and management of hepatitis C. Its products include Ribasphere RibaPak (ribavirin, USP) tablets, which help to reduce pill burden while providing patients with treatment that is biologically equivalent to other ribavirin medications; INFERGEN (interferon alfacon-1) to treat chronic hepatitis C in patients 18 years of age or older with compensated liver disease; Ribasphere (ribavirin, USP) tablets and capsules, which are antiviral medications for use in combination with other drugs for the treatment of chronic hepatitis C; and KD020, a reversible tyrosine kinase inhibitor that targets EGFR, HER2, VEGFR 2/3, and Src in autosomal dominant polycystic kidney disease (PKD). The company also provides various services and programs to support patients, prescribers, and pharmacies, including patient assistance programs to provide free medication to patients with limited or no insurance coverage; temporary shipments for patients on current or recent therapy; and nurse support services. In addition, it develops medicines in oncology, infectious diseases, immunology, and neurodegenerative diseases. The company was formerly known as Kadmon Holdings. Kadmon Corporation was incorporated in 2009 and is based in New York, New York with operations in Warrendale, Pennsylvania; and Boston, Massachusetts.

GliaPharm is a Swiss-based biotechnology company that offers treatments for neurological and psychiatric disorders. GliaPharm's innovative therapeutic approach is to target glial cells , the 'support cells' of neurons, to sustain and enhance brain metabolism in pathological conditions. Their vision is to become a leading biotechnology company with a focus on glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions. GliaPharm is a Swiss biotechnology company active in the development of treatments for neurological and psychiatric diseases. The innovative therapeutic approach of GliaPharm is to target glial cells , or 'support cells' of neurons, to support and improve brain metabolism under certain pathological conditions. Their vision is to become a leader in the development of glial cell targeting agents that act as neuroprotective agents and maintain cognitive functions.

RadioMedix, Inc. is a private company headquartered in Houston, TX, that engages in research and development of radiopharmaceuticals for diagnosis and therapy of cancer. The firm was founded by Ebrahim S. Delpassand, who is currently the CEO of the company.\nThe company says this about itself: RadioMedix, Inc. is a clinical-stage biotechnology company, and sponsor of the AlphaMedix? trial, based in Houston and Humble, Texas. The company is focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. RadioMedix is developing radiopharmaceuticals for PET imaging and therapy (alpha- and beta-labeled agents). The company established contract service facilities for academic and industrial partners including a drug discovery center for the early probe development, a pre-clinical core facility for in vitro and in vivo evaluation of radiopharmaceuticals, and cGMP and analytical suite for Phase I-III clinical trials, and the large-scale post-approval commercial manufacturing facility, the Spica Center.

Part of Cerecin, Inc., Neuera Pharmaceuticals, Inc. is a company headquartered in Broomfield, CO, that develops drugs for neurodegenerative diseases.

NXXI, Inc. operates as a nutritional bioscience company. It primarily develops and markets raw materials, formulations, compounds, blends and bulk and other materials to third-party non-end users to be further fabricated, blended or packaged for ultimate sales to end-users as nutritional supplements. The company was founded on June 29, 1983 and is headquartered in Purchase, NY.